secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003998
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M
--------------------------------------------------------------------------------

- Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.
- Full year 2023 U.S. net product revenue ~$366M: SYFOVRE $275M, EMPAVELI $91M.
- SYFOVRE: ~62,000 doses in Q4, ~160,000 total in 2023; ~95% of GA patients use SYFOVRE.
- EMPAVELI: 97% compliance; >50% existing and >90% new patients use Injector since Oct approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/0001193125-24-003998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312524003998/d51181d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer